Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis

88Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

Abstract

Seventeen diabetic patients with moderate to mild foot lesions associated with 20 osteomyelitic bones diagnosed by both bone scan and bone biopsy received rifampicin plus ofloxacin for a median duration of 6 months. Cure was defined as disappearance of all signs and symptoms of infection at the end of the treatment and absence of relapse during follow up. At the end of the treatment period, cure was achieved in 15 patients (88.2%) and was maintained in 13 patients (76.5%) at the end of an average post-treatment follow-up of 22 months. No serious drug-related adverse events were recorded. © 2001 The British Society for Antimicrobial Chemotherapy.

Cite

CITATION STYLE

APA

Senneville, E., Yazdanpanah, Y., Cazaubiel, M., Cordonnier, M., Valette, M., Beltrand, E., … Mouton, Y. (2001). Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis. Journal of Antimicrobial Chemotherapy, 48(6), 927–930. https://doi.org/10.1093/jac/48.6.927

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free